Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 27;20(2):e0311214.
doi: 10.1371/journal.pone.0311214. eCollection 2025.

Study protocol: Exploratory trial of Forza™, an osmotin-based nutraceutical as adjuvant for the treatment of progressive multiple sclerosis

Viola Costa  1 , Kenda Aluan  1 , Irene Schiavetti  2 , Caterina Bason  3 , Tiziana Vigo  3 , Elisa Leveraro  3 , Corrado Cabona  4 , Valeria Prada  5 , Mauro Costagli  1   3 , Vincenzo Daniele Boccia  1 , Bruno Ruggiero  6 , Giampaolo Brichetto  7 , Marco Salvetti  8   9 , Maria Pia Sormani  2   3 , Gianluigi Mancardi  1 , Matilde Inglese  1   3 , Mario Alberto Battaglia  5
Affiliations

Study protocol: Exploratory trial of Forza™, an osmotin-based nutraceutical as adjuvant for the treatment of progressive multiple sclerosis

Viola Costa et al. PLoS One. .

Abstract

Background: Multiple Sclerosis (MS) is the first cause of non-traumatic neurological disability in young adults. Primary and secondary progressive MS are still lacking effective treatments. A new nutraceutical product made of lyophilised leaves of bioengineered kiwi plants (Actinidia deliciosa) overexpressing osmotin has recently been developed. Osmotin is a protein associated with stress adaptation in plant cells and it shares anti-inflammatory and neuroprotective properties with mammalian adiponectin. The aim of this study is to explore the safety and the efficacy of osmotin in progressive MS (PMS).

Methods: This is a prospective, multicenter, single-arm interventional, baseline vs treatment study that will be carried out by two Italian MS centers, where a total of fifty PMS patients will be recruited. Every patient will take a daily dosage of 5 grams of an osmotin-based nutraceutical, named Forza™ (9th Dimension Biotech, Inc.), for 6 months. Two pre-treatment assessments, at -6 months (-6M) and at baseline visit (M0), and two post-treatment assessments, at month 1 (M1), and at month 6 (M6) will be carried out. ForzaTM safety and activity, assessed by serum Neurofilaments Light (NfL) Chain quantification, are the primary outcomes of the study. Additional assessments will consist of clinical and neuropsychological evaluations, patient reported outcomes (PROs), brain magnetic resonance imaging (MRI), motor evoked potentials (MEPs) and optical coherence tomography (OCT).

Discussion: Disease modifying treatments in MS usually target inflammatory pathways with excellent results on reducing relapse associated disability but fail in preventing progression independent from relapse activity. This is a proof-of-concept study aimed at exploring the safety and the activity of an osmotin-based nutraceutical as an adjuvant treatment in PMS patients.

Trial registration: The trial was registered on July 10th 2023 at www.clinicaltrials.gov having identifier NCT05937802.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. The Lancet Neurology. 2010. May;9(5):520–32. doi: 10.1016/S1474-4422(10)70064-8 - DOI - PubMed
    1. Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, et al.. How patients with multiple sclerosis acquire disability. Brain. 2022. Feb 1;145(9). doi: 10.1093/brain/awac016 - DOI - PMC - PubMed
    1. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death and Differentiation [Internet]. 2010. Jul 1;17(7):1083–91. Available from: https://pubmed.ncbi.nlm.nih.gov/19927157/ doi: 10.1038/cdd.2009.179 - DOI - PubMed
    1. Dangond F, Donnelly A, Hohlfeld R, Lubetzki C, Kohlhaas S, Leocani L, et al.. Facing the urgency of therapies for progressive MS—a Progressive MS Alliance proposal. Nature Reviews Neurology. 2021. Jan 22. doi: 10.1038/s41582-020-00446-9 - DOI - PubMed
    1. Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, et al.. Silent progression in disease activity–free relapsing multiple sclerosis. Annals of Neurology. 2019. Mar 30;85(5):653–66. doi: 10.1002/ana.25463 - DOI - PMC - PubMed

Publication types

Associated data